BioCentury
ARTICLE | Product Development

Sept. 4 Quick Takes: HiFiBiO in second cancer deal with Gilead; plus Bridgewest-Pfizer, Amarin, Intercept, Santhera-Idorsia, CMS, Ascendis

September 5, 2020 12:48 AM UTC

Gilead, HiFiBiO partner on AML
HiFiBiO Therapeutics has closed its second partnership with the Kite Pharma Inc. unit of Gilead Sciences Inc. (NASDAQ:GILD), this time using its antibody and single-cell profiling technology to discover targets for acute myelogenous leukemia (AML) and antibodies specific for the disease that could be used in cell therapies. Kite will have an exclusive option to any targets discovered; HiFiBiO will receive an undisclosed upfront payment and is eligible for undisclosed milestones and royalties (see “Series C Attracts Kite”).

In deal Down Under, Bridgewest to transform Pfizer site into CDMO
The Bridgewest Group has purchased an Australian cGMP biologics manufacturing facility from  Pfizer Inc. (NYSE:PFE) for an undisclosed amount. The investment company, which is led by Chairman Massih Tayebi and counts BioDuro LLC and Formex LLC among its investments, plans to develop the Adelaide-based site into a full-service CDMO. Bridgewest Australia Biotech President and CEO Ian Wisenberg said the deal marks the firm’s first acquisition in Australia...